| Michael Buys, MD | |
|
8868 Saddleback Rd, Park City, UT 84098 | |
| (801) 205-1040 | |
| Not Available |
| Full Name | Michael Buys |
|---|---|
| Gender | Male |
| Speciality | Anesthesiology |
| Experience | 19 Years |
| Location | 8868 Saddleback Rd, Park City, Utah |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1003955014 | NPI | - | NPPES |
| Facility Name | Location | Facility Type |
|---|---|---|
| University Of Utah Hospitals And Clinics | Salt lake city, UT | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| University Of Utah Adult Services | 0941525273 | 1459 |
News Archive
Researchers at Uppsala University have cloned a T-cell receptor that binds to an antigen associated with prostate cancer and breast cancer. T cells that have been genetically equipped with this T-cell receptor have the ability to specifically kill prostate and breast cancer cells.
Some children conceived by a common method of IVF could be carrying chunks of bacterial DNA in their chromosomes, according to a study in mice. The researchers who conducted the work say that such accidental genetic modification would be very rare, but they argue that fertility doctors should take more precautions to exclude it.
Merck, known as MSD outside the United States and Canada, today announced financial results for the first quarter of 2011.
Researchers at Rensselaer Polytechnic Institute today announced the release of a software program capable of quickly identifying molecules that show promise for future medicines. The software program enables drug makers to comb through enormous databases of potential molecules and identify the ones that have sound medicinal properties.
Medivir AB, the research-based speciality pharmaceutical company focused on the development of high-value treatments for infectious diseases, announces that its development partner, Janssen R&D Ireland has broadened its clinical collaboration agreement with Bristol-Myers Squibb Company.
› Verified 1 days ago
| Entity Name | U U Anesthesiology Department School Of Medicine |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1134158322 PECOS PAC ID: 8527963966 Enrollment ID: O20031128000007 |
News Archive
Researchers at Uppsala University have cloned a T-cell receptor that binds to an antigen associated with prostate cancer and breast cancer. T cells that have been genetically equipped with this T-cell receptor have the ability to specifically kill prostate and breast cancer cells.
Some children conceived by a common method of IVF could be carrying chunks of bacterial DNA in their chromosomes, according to a study in mice. The researchers who conducted the work say that such accidental genetic modification would be very rare, but they argue that fertility doctors should take more precautions to exclude it.
Merck, known as MSD outside the United States and Canada, today announced financial results for the first quarter of 2011.
Researchers at Rensselaer Polytechnic Institute today announced the release of a software program capable of quickly identifying molecules that show promise for future medicines. The software program enables drug makers to comb through enormous databases of potential molecules and identify the ones that have sound medicinal properties.
Medivir AB, the research-based speciality pharmaceutical company focused on the development of high-value treatments for infectious diseases, announces that its development partner, Janssen R&D Ireland has broadened its clinical collaboration agreement with Bristol-Myers Squibb Company.
› Verified 1 days ago
| Entity Name | Mountain West Anesthesia Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1558391763 PECOS PAC ID: 9032018502 Enrollment ID: O20040103000057 |
News Archive
Researchers at Uppsala University have cloned a T-cell receptor that binds to an antigen associated with prostate cancer and breast cancer. T cells that have been genetically equipped with this T-cell receptor have the ability to specifically kill prostate and breast cancer cells.
Some children conceived by a common method of IVF could be carrying chunks of bacterial DNA in their chromosomes, according to a study in mice. The researchers who conducted the work say that such accidental genetic modification would be very rare, but they argue that fertility doctors should take more precautions to exclude it.
Merck, known as MSD outside the United States and Canada, today announced financial results for the first quarter of 2011.
Researchers at Rensselaer Polytechnic Institute today announced the release of a software program capable of quickly identifying molecules that show promise for future medicines. The software program enables drug makers to comb through enormous databases of potential molecules and identify the ones that have sound medicinal properties.
Medivir AB, the research-based speciality pharmaceutical company focused on the development of high-value treatments for infectious diseases, announces that its development partner, Janssen R&D Ireland has broadened its clinical collaboration agreement with Bristol-Myers Squibb Company.
› Verified 1 days ago
| Entity Name | University Of Utah Adult Services |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1114321981 PECOS PAC ID: 0941525273 Enrollment ID: O20150209001683 |
News Archive
Researchers at Uppsala University have cloned a T-cell receptor that binds to an antigen associated with prostate cancer and breast cancer. T cells that have been genetically equipped with this T-cell receptor have the ability to specifically kill prostate and breast cancer cells.
Some children conceived by a common method of IVF could be carrying chunks of bacterial DNA in their chromosomes, according to a study in mice. The researchers who conducted the work say that such accidental genetic modification would be very rare, but they argue that fertility doctors should take more precautions to exclude it.
Merck, known as MSD outside the United States and Canada, today announced financial results for the first quarter of 2011.
Researchers at Rensselaer Polytechnic Institute today announced the release of a software program capable of quickly identifying molecules that show promise for future medicines. The software program enables drug makers to comb through enormous databases of potential molecules and identify the ones that have sound medicinal properties.
Medivir AB, the research-based speciality pharmaceutical company focused on the development of high-value treatments for infectious diseases, announces that its development partner, Janssen R&D Ireland has broadened its clinical collaboration agreement with Bristol-Myers Squibb Company.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Michael Buys, MD 8868 Saddleback Rd, Park City, UT 84098 Ph: (801) 205-1040 | Michael Buys, MD 8868 Saddleback Rd, Park City, UT 84098 Ph: (801) 205-1040 |
News Archive
Researchers at Uppsala University have cloned a T-cell receptor that binds to an antigen associated with prostate cancer and breast cancer. T cells that have been genetically equipped with this T-cell receptor have the ability to specifically kill prostate and breast cancer cells.
Some children conceived by a common method of IVF could be carrying chunks of bacterial DNA in their chromosomes, according to a study in mice. The researchers who conducted the work say that such accidental genetic modification would be very rare, but they argue that fertility doctors should take more precautions to exclude it.
Merck, known as MSD outside the United States and Canada, today announced financial results for the first quarter of 2011.
Researchers at Rensselaer Polytechnic Institute today announced the release of a software program capable of quickly identifying molecules that show promise for future medicines. The software program enables drug makers to comb through enormous databases of potential molecules and identify the ones that have sound medicinal properties.
Medivir AB, the research-based speciality pharmaceutical company focused on the development of high-value treatments for infectious diseases, announces that its development partner, Janssen R&D Ireland has broadened its clinical collaboration agreement with Bristol-Myers Squibb Company.
› Verified 1 days ago
Dr. Nathaniel David Kofford, M.D., MSPH Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 900 Round Valley Drive, Park City, UT 84060 Phone: 435-658-7000 Fax: 801-990-1912 | |
Lee Gerstein, M.D. Anesthesiology Medicare: Not Enrolled in Medicare Practice Location: 1439 Willow Loop, Park City, UT 84098 Phone: 425-785-4141 | |
Dr. Watson Allen Bowes Iii, M.D. Anesthesiology Medicare: Not Enrolled in Medicare Practice Location: 7905 Long Rifle Rd, Park City, UT 84098 Phone: 801-442-5692 | |
Courtney Mitchell Bailey, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 900 Round Valley, Park City Medical Center, Park City, UT 84060 Phone: 435-658-7000 Fax: 801-733-5618 | |
Dr. Andrew P. Talbott, M.D. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 1122 Center Dr Ste D350, Park City, UT 84098 Phone: 435-714-7277 Fax: 435-214-2254 | |
Dr. Joseph Morelli, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 900 Round Valley, Park City Medical Center, Park City, UT 84060 Phone: 435-658-7000 |